• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Polaryx Therapeutics, Inc. - Common Stock (NQ:PLYX)

    5.700 -0.420 (-6.86%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Polaryx Therapeutics, Inc. - Common Stock

    News headline image
    Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
    Company selected as a Diamond honoree for Excellence in Pediatric Care 
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
    Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day. 
    Via Stocktwits
    Topics ETFs
    News headline image
    Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What's Going On With Polaryx Therapeutics Stock Wednesday? ↗
    Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement. 
    Via Benzinga
    News headline image
    Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans ↗
    Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders. 
    Via Benzinga
    News headline image
    Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
    Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil) 
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Welcomes New Members of the Board of Directors
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
    Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug... 
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.